1. A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors. (11th November 2020) Authors: Ma, Yuxiang; Fang, Wenfeng; Zhao, Hongyun; Bathena, Sai Praneeth; Tendolkar, Amol; Sheng, Jennifer; Zhang, Li Journal: Oncologist Issue: Volume 26:Number 4(2021) Page Start: e549 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors. (2nd May 2019) Authors: Ma, Yuxiang; Fang, Wenfeng; Zhang, Yang; Yang, Yunpeng; Hong, Shaodong; Zhao, Yuanyuan; Tendolkar, Amol; Chen, Lu; Xu, Dong; Sheng, Jennifer; Zhao, Hongyun; Zhang, Li Journal: Oncologist Issue: Volume 24:Number 7(2019) Page Start: 891 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. Issue 4 (5th April 2022) Authors: Kang, Yoon-Koo; Reck, Martin; Nghiem, Paul; Feng, Yan; Plautz, Gregory; Kim, Hye Ryun; Owonikoko, Taofeek K; Boku, Narikazu; Chen, Li-Tzong; Lei, Ming; Chang, Han; Lin, Wen Hong; Roy, Amit; Bello, Akintunde; Sheng, Jennifer Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 4(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Challenges and Opportunities With Oncology Drug Development in China. Issue 2 (8th March 2018) Authors: Bajaj, Gaurav; Gupta, Manish; Wang, Hwei‐Gene Heidi; Barrett, Jeffrey S.; Tan, Matthew; Rupalla, Katrin; Bertz, Richard; Sheng, Jennifer Journal: Clinical pharmacology & therapeutics Issue: Volume 105:Issue 2(2019) Page Start: 363 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?. Issue 9 (11th June 2022) Authors: Zheng, Songmao; Prell, Rodney; Sheng, Jennifer; Wang, Yow‐Ming; Hamuro, Lora Journal: Clinical and translational science Issue: Volume 15:Issue 9(2022) Page Start: 2096 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical Benefit‐Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors. (14th February 2021) Authors: Sheng, Jennifer; Zhang, Jason; Baudelet, Christine; Roy, Amit Journal: Journal of clinical pharmacology Issue: Volume 61:Number 8(2021) Page Start: 1045 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. (15th September 2017) Authors: Sheng, Jennifer; Srivastava, Shivani; Sanghavi, Kinjal; Lu, Zheng; Schmidt, Brian J.; Bello, Akintunde; Gupta, Manish Other Names: Lee Lucy guestEditor.; Lewis Lionel D. guestEditor. Journal: Journal of clinical pharmacology Issue: Volume 57(2017)Supplement 10 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. (October 2017) Authors: Sheng, Jennifer; Srivastava, Shivani; Sanghavi, Kinjal; Lu, Zheng; Schmidt, Brian J.; Bello, Akintunde; Gupta, Manish Other Names: Lee Lucy guestEditor. Journal: Journal of clinical pharmacology Issue: Volume 57(2017)Supplement 10 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth. (5th July 2017) Authors: Dimopoulos, Meletios A.; Lonial, Sagar; White, Darrell; Moreau, Philippe; Palumbo, Antonio; San‐Miguel, Jesus; Shpilberg, Ofer; Anderson, Kenneth; Grosicki, Sebastian; Spicka, Ivan; Walter‐Croneck, Adam; Magen, Hila; Mateos, Maria‐Victoria; Belch, Andrew; Reece, Donna; Beksac, Meral; Bleickardt, ... Journal: British journal of haematology Issue: Volume 178:Number 6(2017) Page Start: 896 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam. (27th February 2015) Authors: Zhang, Hefei; Sheng, Jennifer; Ko, Jin H.; Zheng, Cheng; Zhou, Wei; Priess, Petra; Lin, Wen; Novick, Steven Journal: Journal of clinical pharmacology Issue: Volume 55:Number 4(2015:Apr.) Page Start: 401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗